Table 2.

Importance weights for the criteria and subcriteria, reported as weight (standard deviation)

Attributes	All patients	VKA users	DOAC users
Main dimensions	N = 44	N = 25	N = 19
Effectiveness	0.60 (0.02)	0.58 (0.03)	0.64 (0.02)
Safety (side effects)	0.27 (0.02)	0.28 (0.03)	0.25 (0.02)
Convenience	0.07 (0.01)	0.08 (0.01)	0.06 (0.01)
Out-of-pocket cost	0.06 (0.01)	0.06 (0.01)	0.06 (0.01)
Consistency ratio	0.16	0.18	0.15
Safety	N = 45	N = 26	N = 19
Major bleedings	0.75 (0.02)	0.76 (0.02)	0.73 (0.03)
Minor bleedings	0.15 (0.02)	0.14 (0.02)	0.16 (0.02)
Gastrointestinal complaints	0.10 (0.01)	0.10 (0.01)	0.11 (0.02)
Consistency ratio	0.03	0.04	0.02
Convenience	N = 43	N = 24	N = 19
Routine blood monitoring	0.40 (0.04)	0.39 (0.04)	0.42 (0.05)
Food restrictions	0.27 (0.03)	0.27 (0.04)	0.28 (0.05)
Intake frequency	0.17 (0.02)	0.19 (0.03)	0.15 (0.02)
Pill type/intake instructions	0.15 (0.02)	0.16 (0.03)	0.15 (0.02)
Consistency ratio	0.002	0.004	0.01

All standard deviations were obtained by bootstrap analysis

DOAC direct (non-VKA) oral anticoagulant, VKA vitamin K antagonist